Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01282008 · ClinicalTrials.gov registry record
Message Testing for Tobacco-Related Corrective Statements
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 627
- Enrollment target
NCT01282008: Completed study, sponsored by National Cancer Institute (NCI).
NCT01282008 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 627 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01282008 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 627 participants
- Enrollment target
Study Summary
BACKGROUND: This document outlines the study design and procedures to be used to evaluate a series of corrective statements to augment consumer knowledge and beliefs about smoking as related to past actions of tobacco companies. The statements were ordered by a U.S. Federal Court in U.S. v. Philip Morris USA, Inc., and are intended to target potential misperceptions resultant of past marketing and promotion practices undertaken by the tobacco industry. OBJECTIVES: The U.S. Department of Justice has asked NCI to take the lead on developing and testing corrective statements with adult and youth audiences to ensure both message comprehension and avoidance of unintended consequences of message exposure, such as boomerang effects, smoking triggers, or knowledge gaps. The court has identified five areas that the statements shall address: 1. The adverse health effects of smoking; 2. The addictiveness of smoking and nicotine; 3. The lack of any significant health benefit from smoking low tar, light, ultra light, mild, and natural cigarettes; 4. The tobacco industry s manipulation of cigarette design and composition to ensure optimum nicotine delivery; 5. The adverse health effects of secondhand smoke. ELIGIBILITY: Message testing will be undertaken with the following audiences: * Current smokers (with an oversample of low socioeconomic status individuals) * General population nonsmokers and former smokers (with an oversample of low socioeconomic status individuals) * Spanish-speaking Hispanics * Youth age 14-17 DESIGN: Both qualitative and quantitative methods (focus groups and post-test comparison group Web-enabled surveys) will be used to develop and test a range of corrective statements in the five areas outlined by the court. * Focus group participants: 48-64 * Survey participants: 2500
Primary Outcome
Tobacco-related knowledge, attitudes, and beliefs were measured at baseline and after exposure to message stimuli.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 627 participants |
| Start Date | 2011-01-21 |
What the finished NCT01282008 record still lists
NCT01282008 is an observational study that tracks outcomes without assigning an intervention. The registered 627 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01282008 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01282008 about?
NCT01282008 is a clinical study titled "Message Testing for Tobacco-Related Corrective Statements". BACKGROUND: This document outlines the study design and procedures to be used to evaluate a series of corrective statements to augment consumer knowledge and beliefs about smoking as related to past actions of tobacco companies. The statements were ordered by a U.S. Federal Court in U.S. v. Philip ...
What is the current status of trial NCT01282008?
This trial is currently completed. The enrollment target is 627 participants. The study started on 2011-01-21.
Who is sponsoring clinical trial NCT01282008?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06040827 · 626 participants
A Multicenter, Postmarket Surveillance Study of Subjects With the Canary canturioTM te Tibial Extension
- NCT05349227 · 625 participants · NA
Comprehensive Outcomes for After Cancer Health
- NCT06103864 · 625 participants · Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
- NCT06230510 · 625 participants · NA
Milk-Tot Study: Impact of Whole Versus Low-fat Milk on Child Health
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI